AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03831412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: Targeting insomnia symptoms to reduce suicidal ideation and sleep problems related to traumatic experience.
Study NCT00419653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Study NCT02951559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Brushing
Description: Nasal brushing will be performed in non-sedated patients as follows. After administration of a local vasoconstrictor (1% epinephrine) with the use of a nasal tampon, inserted into the nasal cavity of the patient to locate the olfactory mucosa lining the nasal vault. A sterile, disposable brush (Copanflock, Copan, Brescia, Italy) will be inserted gently rolled on the mucosal surface, withdrawn,and immersed in 0.9% saline solution, UTM (Universal Transporter Medium) or 4% formaldehyde. Two swabs will be collected for each nostril.
Study NCT02340754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Study NCT02340754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MS Education Control
Study NCT01474460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: phytonadione
Description: Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
Study NCT03831412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ERRT
Description: Targeting post-trauma nightmares to reduce suicidal ideation and sleep problems related to traumatic experience.
Study NCT01712165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ANMUM Materna
Study NCT01712165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (milk powder)
Study NCT04283682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early skin-to-skin combined with breast-feeding
Description: Premature infants in the intervention group have access to skin-to-skin once a day for 1 hour at least once no ventilation support needed. During the skin-to-skin period,the breastfeeding is encouraged for about 5-10 minutes. The whole intervention stop until the baby achieve the full oral feeding.
Study NCT02619110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: backward walking treadmill training
Description: subjects accepted 30 minutes backward walking treadmill training. a week for four weeks.
Study NCT02619110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional physical therapy
Description: subjects accepted 30 minutes traditional physical therapy three times a week for four weeks
Study NCT03699462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma solution-A injection
Description: The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
Study NCT03699462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Albumin
Description: The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
Study NCT00707278 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).
Study NCT00707278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
Study NCT00707278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
Study NCT02074969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Nail 3
Description: Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by Gamma Nail 3.
Study NCT02074969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFNA
Description: Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by PFNA.
Study NCT02777970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride/Dexketoprofen Trometamol
Study NCT02777970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride/Paracetamol
Study NCT02777970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02777970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02777970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01194531 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 24 Chromosome Aneuploidy Screening with Parental Support
Description: Preimplantation Genetic Screening (PGS)
Study NCT02900105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg (1 tablet) once a day for 4 months
Study NCT01008956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
Description: Intramuscular injection, one dose
Study NCT01328106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Repeating oral dose
Study NCT00759785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab (MK0646)
Description: Single intravenous infusion
Study NCT03030144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evidence based nursing recommendations
Description: The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
Study NCT02149823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 24 Intranasal Units (IU)
Study NCT02149823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 40 Intranasal Units (IU)
Study NCT02149823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Placebo
Study NCT01785511 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: UVA Radiation
Description: UVA radiation exposure for 20 minutes
Study NCT01785511 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVA Radiation
Description: UVA radiation exposure for 20 minutes
Study NCT03976167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen administration with Common nasal cannula
Description: Oxygen administration during elective flexible bronchoscopy in children with high flow nasal cannula with inspired oxygen fraction 1.
Study NCT03976167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen administration with high flow nasal cannula, device Airvo2 Fisher and Pykel
Study NCT00915486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Good Standard of Care (GSoC)
Description: Procedural treatment twice per week
Study NCT00915486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Topical fibrin as an adjunct to GSoC twice per week
Study NCT00915486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: I-020201
Description: Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
Study NCT04809857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT04809857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT03047720 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lully Sleep Guardian
Description: In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study.
Study NCT01099501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
Description: Oxepa will be administered(enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding
Study NCT01099501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oxepa
Description: A dose determined by a patient's energy expenditure and tolerance of enteral feeding.
Study NCT01099501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
Study NCT00226668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCRF
Description: hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
Study NCT00226668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo hCRF
Description: placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
Study NCT04497870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peppermint oil
Description: Administration of peppermint oil at one of two daily doses.
Study NCT04497870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: Administration of peppermint oil at one of two daily doses.
Study NCT02002039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythropoietin
Description: 500 units /kg /day every other day for 5 doses
Study NCT02002039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: 500 units /kg /day every other day for 5 doses
Study NCT01474460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytonadione
Description: Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
Study NCT03350243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCENT Intervention
Description: 1. Acceptance and Commitment Therapy approach: engaging families through structured individual or group sessions within the NICU and continue this support once discharged.~2. Care coordination: supporting providers in clear communication when liaising across various levels of care as well as supporting families in system and resource navigation.~3. Anticipatory guidance: proactive education targeting normal challenges in caring for a child who required intensive care support.
Study NCT01627080 — intervention group
Intervention type: OTHER
Intervention: Cardiac Biomarker Blood Draws
Description: Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
Study NCT00350701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgel
Description: androgel 5g
Study NCT00350701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgel 10g
Description: androgel 10g
Study NCT00350701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03145467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
Study NCT03145467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients
Study NCT02276391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/HCTZ combination
Study NCT02276391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT00817804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the V60 Mask Ventilator
Description: The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
Study NCT03331029 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: transesophageal investigation
Description: Comparison of 3D ultrasound with transesophageal echocardiography
Study NCT01803230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine supplementation
Description: creatine supplementation
Study NCT00413634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anagrelide hydrochloride
Description: Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
Study NCT00413634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anagrelide hydrochloride
Description: Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
Study NCT03690284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Double Lumen Tube
Description: Patient will be intubated with Mallinckrodt Double Lumen endotracheal tube for single lung ventilation during thoracic surgery
Study NCT03690284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight Double Lumen Tube
Description: Patient will be intubated with the VivaSight double lumen endotracheal tube with an integrated camera for single lung ventilation during thoracic surgery
Study NCT00729885 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Goggle with 20 degree error
Description: The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
Study NCT00729885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized Goggle
Description: The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
Study NCT00917631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Co-bedding (caring for twins in the same incubator)
Description: Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes).
Study NCT01031186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: GSK356278
Study NCT01031186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: PLACEBO
Study NCT03229096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib plus XELOX
Description: three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks.
Study NCT02429752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
Study NCT00530049 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Study NCT00530049 — intervention group
Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Study NCT00530049 — intervention group
Intervention type: PROCEDURE
Intervention: psychosocial assessment and care
Study NCT00530049 — intervention group
Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Study NCT03732950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00988897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXALIPLATIN (SR96669)
Description: Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
Study NCT00988897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FLUOROURACIL (5-FU)
Description: Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
Study NCT00988897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEUCOVORIN (LV)
Description: Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
Study NCT01322594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI2338
Description: MEDI2338 single intravenous (IV) dose (lowest dose)
Study NCT01322594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI2338
Description: MEDI2338 single IV dose (next highest dose)
Study NCT01625377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
Study NCT01322594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI2338
Description: MEDI2338 single IV dose (highest dose)
Study NCT01322594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single IV dose
Study NCT02792114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02792114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesothelin-targeted T cells
Study NCT02792114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Study NCT01222754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 1. With radiation therapy five days per week, concurrent doses of lenalidomide daily in a standard Phase I dose escalation design.~2. Maintenance dosing of lenalidomide, post-radiation, for 21 days of a 28 day course.
Study NCT01222754 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT, 54-59.4 Gy
Description: Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
Study NCT03016481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: the Community Health Worker -Personalized Support for Progress
Description: Subjects will meet with their CHW to prioritize their needs detected by the Promote psychosocial screening and identify their preferences for intervention using a secure, online card sorting tool called Optimal Sort. The subject will explain her/his rationale for each decision to the CHW, allowing them both to begin to identify goals. The prioritization survey results provide subjects a personalized package of services that map onto the four main intervention options: legal help, problem solving therapy, medical consultation, or social services.
Study NCT03016481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual- Social Worker
Description: Based on their assessment and the subjects' needs, brief onsite interventions are provided and consist of empowerment focused advocacy, IPV education, community referrals, and safety planning. Participants determine follow-up. This will be a short-term interaction as routinely practiced across hospital settings.
Study NCT03074435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indoor residual sprayings
Description: Houses will be spayed with this formulation containing Pyrimiphos methyl.